作者: Evelien Zoons , Marina A.J. Tijssen , Yasmine E.M. Dreissen , Marenka Smit , Jan Booij
DOI: 10.3390/BIOM10060880
关键词: Placebo-controlled study 、 Gastroenterology 、 Internal medicine 、 Cervical dystonia 、 Dystonia 、 Serotonin transporter 、 Escitalopram 、 Serotonin reuptake inhibitor 、 Medicine 、 Iodobenzamide 、 Clinical Global Impression
摘要: Purpose: The pathophysiology of cervical dystonia (CD) is thought to be related changes in dopamine and serotonin levels the brain. We performed a double-blind trial with escitalopram (selective reuptake inhibitor; SSRI) patients CD. Here, we report on D2/3 receptor (D2/3R), transporter (DAT) (SERT) binding potential (BPND) after six-week treatment course or placebo. Methods: CD had [123I]FP-CIT SPECT (I-123 fluoropropyl carbomethoxy-3 beta-(4-iodophenyltropane) single-photon emission computed tomography) scans, quantify extrastriatal SERT striatal DAT, [123I]IBZM iodobenzamide SPECT) scans D2/3R BPND before six weeks either Treatment effect was evaluated Clinical Global Impression scale for dystonia, jerks psychiatric symptoms, both by physicians patients. Results: In treated placebo there were no significant differences SERT, DAT BPND. Comparing (n = 8) showed trend (p 0.13) towards lower SSRI group (median occupancy 64.6%). After escitalopram, who reported positive symptoms significantly higher compared did not experience an effect. Conclusion: Higher associated subjective